Stay updated on Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial
Sign up to get notified when there's something new on the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page.

Latest updates to the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now shows Revision: v3.4.2, replacing the previous v3.4.1. This appears to be a minor metadata update with no substantive changes to the study content or displayed information.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 with no visible changes to page content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedMinor UI and metadata updates: added the glossary toggle label, standardized capitalization for QC criteria labels, updated No FEAR Act data labeling, and versioned the revision to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check61 days agoChange DetectedRevision updated to v3.3.4, replacing v3.3.3, indicating a minor metadata update to the page.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page now includes a dedicated Locations section listing Texas as a site, while the prior Texas Locations heading was removed. The HHS Vulnerability Disclosure link was removed and the revision version updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page.